Comparative panel sequencing of DNA variants in cf-, ev- and tumorDNA for pancreatic ductal adenocarcinoma patients

PDAC has a poor prognosis. To improve treatment and disease outcome, personalized medicine utilizes next generation sequencing aiming at characterizing actionable DNA variants from samples obtained by fine-needle biopsy. Recently, the focus increasingly shifts to blood-based liquid biopsies including circulating-free (cf)DNA or DNA isolated from extracellular vesicles (evDNA). To evaluate detection performance of DNA alterations, in our study we directly compared tumor-, cf- and evDNA from patients with advanced PDAC upon panel sequencing. Copy number variations (CNVs), single nucleotide variants (SNVs) as well as insertions and deletions (indels) were compared for their concordance with tumorDNA.